First Albany Upgrades Barr Labs to 'Strong Buy'

Analyst Adam Greene says he sees potential upside to his estimates, following the FDA's approval of Barr's oral contraceptive

First Albany upgraded Barr Laboratories (BRL ) to strong buy from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.